30
300832.SHE Shenzhen New Industries Biomedical
- Market cap
- CNY 50.3B
- P/E
- 29.1x
- P/B
- 5.17x
- ROE
- 19.7%
- Dividend yield
- 2.03%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300832.SHE undervalued?
Graham number300832.SHE trades 158.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shenzhen New Industries Biomedical fundamental analysis
No fundamental analysis for Shenzhen New Industries Biomedical yet.
Shenzhen New Industries Biomedical stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shenzhen New Industries Biomedical
Shenzhen New Industries Biomedical Engineering Co., Ltd., engages in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals in China and internationally. It offers immunoassay analyzers, biochemistry/electrolyte, integrated system, lab automation, molecular diagnostics, hemolumi and rapid test solutions. The company was founded in 1995 and is based in Shenzhen, China.
Full company profileShenzhen New Industries Biomedical financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shenzhen New Industries Biomedical annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 923M | 1.14B | 1.38B | 1.68B | 2.19B | 2.55B | 3.05B | 3.93B | 4.54B | 4.58B | 4.93B |
| Gross Profit | 727M | 897M | 1.12B | 1.34B | 1.69B | 1.81B | 2.14B | 2.87B | 3.27B | 3.17B | 3.52B |
| Operating Income | 501M | 630M | 808M | 899M | 1.10B | 1.14B | 1.50B | 1.90B | 2.11B | 1.81B | 2.17B |
| EBITDA | 507M | 633M | 766M | 882M | 1.10B | 1.15B | 1.44B | 1.89B | 2.11B | 2.06B | 2.12B |
| Net Income | 452M | 538M | 694M | 773M | 939M | 974M | 1.33B | 1.65B | 1.83B | 1.62B | 1.85B |
| EPS | 0.64 | 0.76 | 0.99 | 0.99 | 1.20 | 1.24 | 1.69 | 2.10 | 2.33 | 2.06 | 2.36 |
| Balance Sheet | |||||||||||
| Total Assets | 1.61B | 2.02B | 2.64B | 3.46B | 5.31B | 6.14B | 7.01B | 8.22B | 9.62B | 9.94B | 10.3B |
| Total Liabilities | 186M | 250M | 275M | 319M | 504M | 524M | 615M | 678M | 1.04B | 796M | 865M |
| Shareholders' Equity | 1.42B | 1.77B | 2.37B | 3.14B | 4.80B | 5.61B | 6.40B | 7.54B | 8.58B | 9.14B | 9.40B |
| Cash & Short-term Investments | 899M | 1.08B | 1.43B | 1.98B | 3.37B | 3.42B | 3.30B | 3.13B | 2.64B | 997M | 1.30B |
| Total Debt | - | - | - | - | 1.20M | 881K | 893K | 3.49M | 2.76M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 487M | 525M | 702M | 832M | 977M | 773M | 962M | 1.42B | 1.36B | 1.52B | - |
| Capital Expenditure | 56.0M | 177M | 285M | 327M | 255M | 343M | 403M | 322M | 439M | 311M | 304M |
| Free Cash Flow | 431M | 348M | 417M | 505M | 722M | 430M | 559M | 1.10B | 917M | 1.21B | 1.71B |
| Ratios | |||||||||||
| ROE | 31.8% | 30.4% | 29.3% | 24.6% | 19.5% | 17.4% | 20.8% | 21.9% | 21.3% | 17.7% | 19.7% |
| ROA | 28.1% | 26.6% | 26.3% | 22.3% | 17.7% | 15.9% | 18.9% | 20.1% | 19.0% | 16.3% | 18.1% |
| Net Profit Margin | 49.0% | 47.2% | 50.2% | 45.9% | 42.8% | 38.3% | 43.6% | 42.1% | 40.3% | 35.4% | 37.6% |
| Debt to Equity | - | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shenzhen New Industries Biomedical dividends
- Dividend yield
- 2.03%
- Forward dividend
- 1.20 CNY
- Payout ratio
- 63.1%
- Ex-dividend date
- May 27, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.02B | 1.30 | 63.1% |
| 2024 | CNY 786M | 1.00 | 43.0% |
| 2023 | CNY 550M | 0.70 | 33.3% |
| 2022 | CNY 472M | 0.60 | 35.5% |
| 2021 | CNY 412M | 0.52 | 42.3% |
| 2020 | CNY 619M | 0.79 | 65.9% |
| 2019 | CNY 619M | 0.79 | 80.1% |
| 2018 | CNY 101M | 0.14 | 14.6% |
| 2017 | CNY 185M | 0.26 | 34.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.9:1 on May 21, 2021.
Who owns Shenzhen New Industries Biomedical
- Insiders 48.54%
- Institutions 22.79%
- Public & others 28.67%
- Shares outstanding 786M
- Free float 328M
Shenzhen New Industries Biomedical company profile
- Company name
- Shenzhen New Industries Biomedical
- Ticker
- 300832.SHE
- ISIN
- CNE100003T39
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 2,785
- Fiscal year end
- December
- Address
- New Industry Biological Building, Shenzhen, China, 518118
- Phone
- 86 755 2650 1514
- Website
- snibe.com
About Shenzhen New Industries Biomedical
Shenzhen New Industries Biomedical Engineering Co., Ltd., engages in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals in China and internationally. It offers immunoassay analyzers, biochemistry/electrolyte, integrated system, lab automation, molecular diagnostics, hemolumi and rapid test solutions. The company was founded in 1995 and is based in Shenzhen, China.
Shenzhen New Industries Biomedical management
6- Dr. Wei RaoChairman of the Board & GM · born 1964
- Ms. Chenliu DingCFO, Accounting Supervisor & Deputy GM · born 1975
- Ms. Haiyan LiuDeputy General Manager · born 1979
- Ms. Lei ZhangSecretary of the Board · born 1982
- Ms. Ting Hua LiDeputy General Manager
- Mr. Jinyun YuanDeputy General Manager · born 1986